Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
Medical Devices & Diagnostics